Medley Capital (MCC) Analysts See $0.15 EPS; Last Week Endocyte, Inc. (ECYT) Coverage

January 14, 2018 - By Adrian Mccoy

Among 4 analysts covering Endocyte (NASDAQ:ECYT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Endocyte had 8 analyst reports since August 5, 2015 according to SRatingsIntel. As per Monday, June 5, the company rating was downgraded by Wedbush. Wedbush upgraded Endocyte, Inc. (NASDAQ:ECYT) on Tuesday, October 3 to “Outperform” rating. RBC Capital Markets maintained it with “Outperform” rating and $10 target in Wednesday, November 4 report. RBC Capital Markets maintained Endocyte, Inc. (NASDAQ:ECYT) rating on Wednesday, August 5. RBC Capital Markets has “Outperform” rating and $13 target. The stock of Endocyte, Inc. (NASDAQ:ECYT) earned “Outperform” rating by Credit Suisse on Thursday, January 21. The firm has “Hold” rating given on Friday, June 2 by Cowen & Co. The rating was downgraded by Cowen & Co on Monday, June 5 to “Market Perform”. The stock has “Hold” rating by Cowen & Co on Monday, October 2. See Endocyte, Inc. (NASDAQ:ECYT) latest ratings:

03/10/2017 Broker: Wedbush Old Rating: Neutral New Rating: Outperform Upgrade
02/10/2017 Broker: Cowen & Co Rating: Hold Maintain

Analysts expect Medley Capital Corporation (NYSE:MCC) to report $0.15 EPS on February, 8.They anticipate $0.04 EPS change or 21.05% from last quarter’s $0.19 EPS. MCC’s profit would be $8.17M giving it 8.78 P/E if the $0.15 EPS is correct. After having $0.16 EPS previously, Medley Capital Corporation’s analysts see -6.25% EPS growth. The stock increased 0.76% or $0.04 during the last trading session, reaching $5.27. About 115,248 shares traded. Medley Capital Corporation (NYSE:MCC) has declined 6.36% since January 14, 2017 and is downtrending. It has underperformed by 23.06% the S&P500.

Investors sentiment decreased to 0.32 in Q3 2017. Its down 0.40, from 0.72 in 2017Q2. It fall, as 14 investors sold Endocyte, Inc. shares while 24 reduced holdings. 4 funds opened positions while 8 raised stakes. 8.27 million shares or 31.84% less from 12.13 million shares in 2017Q2 were reported. Leisure Capital Mgmt has invested 0.03% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). Moreover, Jpmorgan Chase And has 0% invested in Endocyte, Inc. (NASDAQ:ECYT). Royal Commercial Bank Of Canada has 0% invested in Endocyte, Inc. (NASDAQ:ECYT). Spark Investment Ltd Llc has 176,700 shares. 2.44M are owned by Fmr. State Street Corp holds 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 17,079 shares. Drw Ltd holds 0% or 11,000 shares. Citadel Limited Liability Company invested in 61,595 shares. Northern Trust Corp invested in 79,036 shares. Retail Bank Of New York Mellon reported 0% stake. Gemmer Asset Management Limited Liability Company invested 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). Bb&T Llc reported 20,750 shares. Wells Fargo And Company Mn stated it has 0% in Endocyte, Inc. (NASDAQ:ECYT). Moreover, Geode Capital Mngmt Lc has 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 208,895 shares. Millennium Limited Liability Corporation has invested 0% in Endocyte, Inc. (NASDAQ:ECYT).

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company has market cap of $194.40 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents. It currently has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

The stock increased 0.50% or $0.02 during the last trading session, reaching $4.06. About 397,519 shares traded. Endocyte, Inc. (NASDAQ:ECYT) has declined 24.78% since January 14, 2017 and is downtrending. It has underperformed by 41.48% the S&P500.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.46, from 1.38 in 2017Q2. It dived, as 14 investors sold Medley Capital Corporation shares while 25 reduced holdings. 14 funds opened positions while 22 raised stakes. 14.56 million shares or 0.78% less from 14.68 million shares in 2017Q2 were reported. Citigroup invested in 6,025 shares or 0% of the stock. Private Advisor Ltd Com has 0% invested in Medley Capital Corporation (NYSE:MCC) for 15,220 shares. Horizon Invs Limited Liability Company stated it has 0.01% of its portfolio in Medley Capital Corporation (NYSE:MCC). 32,534 are owned by Pinebridge Invests Lp. Macquarie Group Limited has invested 0% in Medley Capital Corporation (NYSE:MCC). Hl Fin Svcs Llc has 22,292 shares for 0% of their portfolio. 1,250 were accumulated by Baystate Wealth Mngmt Ltd Com. Ameriprise Financial owns 0% invested in Medley Capital Corporation (NYSE:MCC) for 28,479 shares. Arete Wealth Advsrs Limited Liability stated it has 0.32% of its portfolio in Medley Capital Corporation (NYSE:MCC). 325,794 were reported by Blackrock. Panagora Asset Mgmt holds 1,967 shares. 28,557 were reported by Stevens Capital Mgmt L P. Invesco Ltd reported 0% in Medley Capital Corporation (NYSE:MCC). Cwm Ltd Llc holds 0% of its portfolio in Medley Capital Corporation (NYSE:MCC) for 6,230 shares. Sei Invests stated it has 0% in Medley Capital Corporation (NYSE:MCC).

Medley Capital Corporation is a business development company. The company has market cap of $287.08 million. The fund seeks to invest in privately negotiated debt and equity securities of small and middle market companies. It currently has negative earnings. It primarily invests in the following sectors: business services; buildings and real estate; automobile; gas and oil; aerospace and defense; home and office furnishings, housewares, and durable consumer products; healthcare, education and childcare; personal, food, and miscellaneous services; retail stores, diversified or conglomerate manufacturing; telecommunications; mining, steel, iron, and non-precious metals; leisure, amusement, motion pictures, and entertainment; chemicals, plastics, and rubber; finance; personal and nondurable consumer products ; beverage, food, and tobacco; containers, packaging, and glass; structure finance securities; machinery (non-agriculture, non-construction, non-electric); diversified or conglomerate service; restaurant and franchise; electronics; and cargo transport.

Among 7 analysts covering Medley Capital Corp (NYSE:MCC), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Medley Capital Corp had 18 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Wells Fargo given on Monday, December 7. Keefe Bruyette & Woods maintained the shares of MCC in report on Thursday, December 7 with “Hold” rating. Jefferies maintained the shares of MCC in report on Tuesday, December 12 with “Hold” rating. Janney Capital reinitiated the stock with “Buy” rating in Wednesday, April 27 report. The rating was downgraded by Janney Capital to “Neutral” on Monday, December 12. The rating was maintained by National Securities on Wednesday, August 12 with “Buy”. The firm earned “Hold” rating on Friday, November 3 by Jefferies. The firm has “Hold” rating given on Monday, June 12 by Keefe Bruyette & Woods. The rating was upgraded by Keefe Bruyette & Woods on Monday, December 7 to “Outperform”. The rating was maintained by UBS with “Neutral” on Wednesday, October 14.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: